Figures & data
Table I. Median survival rate for different stages of ovarian cancer.
Table II. Marketed drug products used in ovarian cancer.
Table III. Chemotherapeutically active agents/drugs used in ovarian cancer.
Table IV. Nanocarrier-based delivery system for ovarian cancer.
Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, et al. 2005. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol. 96:10–8. Sun J, Deng Y, Wang S, Cao J, Gao X, Dong X. 2010. Liposomes incorporating sodium deoxycholate for hexamethylmelamine HMM oral delivery: development, characterization, and in vivo evaluation. Drug Deliv. 17:164–70. Uchegbu IF, Double JA, Kelland LR, Turton JA, Florence AT. 1996The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models. J Drug Targeting. 3: 399–409. Bayindir ZS, Yuksel N. 2010. Characterization of niosomes prepared with various non ionic surfactants for paclitaxel oral delivery. J Pharm Sci. 99:2049–2060. Bai S, Thomas C, Rawat A, Ahsan F. 2006. Recent progress in dendrimer-based nanocarriers. Crit Rev Ther Drug Carrier Syst. 23:437–495. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, et al. 2011. A phase II evaluation of nanoparticles, albumin-bound paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 122:111–5. Zhang P, Chen L, Zhang Z, Lin L, Li Y. 2010. Pharmacokinetics in rats and efficacy in murine ovarian cancer model for solid lipid nanoparticles loading docetaxel. J Nanosci Nanotechnol. 10:7541–4. Li R, Eun JS, Lee MK. 2011. Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration. Arch Pharm Res. 34:331–7. Loftsson T, Vogensen SB, Brewster ME, Konradsdottir F. 2007. Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci. 96:2532–2546. Chauhan SC, Kumar D, Jaggi M. 2009. Mucins in ovarian cancer diagnosis and therapy. J Ovarian Res. 2:21–26. Emami J, Rezazadeh M, Varshosaz J, Tabbakhian M, Aslani A. 2012. Formulation of LDL Targeted Nanostructured Lipid Carriers Loaded with Paclitaxel: A Detailed Study of Preparation, Freeze Drying Condition, and In Vitro Cytotoxicity. J Nanomater. 2012:1–10.